Pancreatic ductal adenocarcinoma (PDAC) — a low-mutation, immunologically cold tumor where neoantigen vaccines (e.g. autogene cevumeran) have shown durable T-cell responses.
New research in Nature demonstrates that RNA neoantigen vaccines can prime long-lived CD8+ T cells in pancreatic cancer. This finding is critical for validating the durability of immune responses generated by RNA-based platforms, a key hurdle for long-term efficacy in aggressive solid tumors.
Memorial Sloan Kettering Cancer Center is running a Phase I trial for resectable pancreatic cancer, evaluating a personalized cancer vaccine (PCV) administered after surgery and atezolizumab, followed by chemotherapy. This design tests the vaccine's role in the adjuvant setting to prevent recurrence in a high-risk population.
National Cancer Institute reports that neoantigen vaccines are keeping kidney and pancreatic cancers at bay. These findings contribute to the growing body of evidence supporting the clinical utility of personalized neoantigen vaccines across multiple solid tumor types.
A completed Phase 1 randomized trial by Washington University School of Medicine evaluated optimized synthetic long peptide (SLP) neoantigen vaccines co-administered with poly-ICLC in pancreatic cancer patients. The study compared vaccine administration following neoadjuvant chemotherapy and surgery versus a window prior to surgery, aiming to assess safety and immunogenicity in the perioperative setting.
The Affiliated Nanjing Drum Tower Hospital is recruiting for a Phase 1/2 trial of a KRAS neoantigen nanovaccine derived from engineered Lactococcus lactis bacterial membranes. The vaccine is administered as adjuvant therapy to post-operative colorectal and pancreatic cancer patients with KRAS mutations, aiming to assess safety, immunogenicity, and preliminary efficacy in preventing recurrence.
Investigator-initiated study led by Wu Wenming is evaluating XH001, a neoantigen cancer vaccine, in resected pancreatic cancer. The single-arm trial tests the efficacy and safety of XH001 in sequential combination with immune checkpoint inhibitors and chemotherapy following surgical resection.
A new Nature publication reports that personalized RNA neoantigen vaccines successfully stimulated T cell responses in pancreatic cancer patients. This finding provides clinical evidence supporting the immunogenic potential of RNA-based platforms in this historically difficult-to-treat malignancy.
Anda Biopharmaceutical has opened an expanded access program for PCNAT-01, a personalized tumor neoantigen peptide vaccine, for patients with resected pancreatic ductal adenocarcinoma. The program targets disease-free patients post-surgery and adjuvant therapy to reduce recurrence risk, subject to regulatory and sponsor review.
Centre Georges Francois Leclerc is initiating a Phase I study of ODI-2001, a personalized DNA neoantigen vaccine combined with a Modified Vaccinia Ankara adjuvant and ipilimumab. The trial targets metastatic or locally advanced colon and pancreatic cancers, starting with dose escalation to determine the maximum tolerated dose.